Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.

Lang KA, Yan J, Draghia-Akli R, Khan A, Weiner DB
Vaccine. 2008 26 (49): 6225-31

PMID: 18692108 · PMCID: PMC4477808 · DOI:10.1016/j.vaccine.2008.07.052

Hepatitis C virus (HCV) represents a major health burden with more than 170 million individuals currently infected worldwide, equaling roughly 3% of the world's population. HCV preferentially infects hepatocytes and is able to persist in up to 70% of infected individuals. It is estimated that up to 30% of chronically infected individuals will go on to develop progressive liver disease as a result of HCV infection, making the virus the leading cause of liver transplantation in the world. Currently there is no vaccine for HCV. In this study, we have taken a multi-step approach to develop a novel genotype 1a/1b consensus HCV NS3/NS4A DNA vaccine able to induce strong cellular immunity. We show that this construct is able to induce strong anti-NS3/NS4A T cell responses in C57BL/6 mice, as well as, in Rhesus macaques. Our data suggest that DNA vaccines encoding HCV proteins NS3/NS4A merit further study in the context of future prophylactic and therapeutic HCV T cell based vaccines.

MeSH Terms (22)

Amino Acid Sequence Animals Carrier Proteins Cell Separation Electroporation Enzyme-Linked Immunosorbent Assay Epitope Mapping Fluorescent Antibody Technique Genotype Hepacivirus Immunity, Cellular Immunization Interferon-gamma Intracellular Signaling Peptides and Proteins Macaca mulatta Mice Mice, Inbred C57BL Molecular Sequence Data Spleen Vaccines, DNA Viral Nonstructural Proteins Viral Proteins

Connections (1)

This publication is referenced by other Labnodes entities: